FindTrial
Sign In

Intermediate dose thromboprophylaxis

DRUG2 trials

Sponsors

UMC Utrecht, University of Iowa

Conditions

COVID 19 Associated CoagulopathyCommunity-acquired Pneumonia, Influenza, COVID-19

Phase 3

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
RecruitingNCT02735707
UMC UtrechtCommunity-acquired Pneumonia, Influenza, COVID-19
Start: 2016-04-11End: 2028-02-29Target: 20000Updated: 2024-07-12

Phase 4

Covid-19 Associated Coagulopathy
CompletedNCT04360824
University of IowaCOVID 19 Associated Coagulopathy
Start: 2020-05-06End: 2021-04-16Updated: 2023-03-01

Related Papers

Evaluating plasma ferritin and suPAR as treatable traits for critically ill patients with COVID-19 treated with anakinra: an exploratory analysis of the immune modulation domain of the REMAP-CAP randomised clinical trial
Critical Care2026-10-01
Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial
Thorax2025-05-139 citations
Elevated tissue factor pathway inhibitor delays thrombin generation in COVID-19 but is not associated with clinical outcomes
Blood Vessels Thrombosis & Hemostasis2025-04-292 citations
Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia
Intensive Care Medicine2025-04-0132 citations
Extracellular histones: a unifying mechanism driving platelet-dependent extracellular vesicle release and thrombus formation in COVID-19.
2024-05-284 citations
A blueprint for a multi-disease, multi-domain Bayesian adaptive platform trial incorporating adult and paediatric subgroups: the Staphylococcus aureus Network Adaptive Platform trial.
2023-12-068 citations
Simvastatin in Critically Ill Patients with Covid-19
New England Journal of Medicine2023-10-2559 citations
Intravenous Vitamin C for Patients Hospitalized With COVID-19
JAMA2023-10-2545 citations
Abstract 261: Tissue Factor Pathway Inhibitor Prolongs The Initiation Of Thrombin Generation And Is Associated With Acute Kidney Injury In Covid-19
Arteriosclerosis Thrombosis and Vascular Biology2023-05-01
Abstract 154: Crossroads Of Immunity And Coagulation: Protease Activity Of Complement Component C1s Inhibits Protein C Activation In Covid-19
Arteriosclerosis Thrombosis and Vascular Biology2023-05-01
Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19
JAMA2023-04-1166 citations
The Relationship Between SARS-CoV-2 Neutralizing Antibody Titers and Avidity in Plasma Collected From Convalescent Nonvaccinated and Vaccinated Blood Donors
The Journal of Infectious Diseases2023-03-274 citations
Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19
JAMA2023-03-2192 citations
The Impact of COVID-19 Research on the Development of Scalable Frameworks for Efficient Clinical Trials in Cardiovascular Medicine
Canadian Journal of Cardiology2023-03-153 citations
Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis.
2022-12-0128 citations
Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study.
2022-09-2211 citations
Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19
JAMA2022-03-22144 citations
Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial
BMJ2022-01-0779 citations
Chronic Oral Anticoagulation Therapy and Prognosis of Patients Admitted to Hospital for COVID‐19: Insights from the HOPE COVID‐19 Registry
International Journal of Clinical Practice2022-01-015 citations
Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19
JAMA2021-10-05208 citations

12 more papers not shown